KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 89 filers reported holding KEROS THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $741,752 | -26.3% | 23,267 | -7.2% | 0.00% | 0.0% |
| Q2 2023 | $1,006,911 | +8.8% | 25,060 | +15.6% | 0.00% | 0.0% |
| Q1 2023 | $925,394 | -8.7% | 21,672 | +2.7% | 0.00% | -50.0% |
| Q4 2022 | $1,013,510 | +38.1% | 21,106 | +8.2% | 0.00% | +100.0% |
| Q3 2022 | $734,000 | +38.8% | 19,511 | +1.9% | 0.00% | 0.0% |
| Q2 2022 | $529,000 | -45.0% | 19,147 | +8.4% | 0.00% | 0.0% |
| Q1 2022 | $961,000 | -15.0% | 17,670 | -8.5% | 0.00% | 0.0% |
| Q4 2021 | $1,130,000 | +51.3% | 19,317 | +2.2% | 0.00% | 0.0% |
| Q3 2021 | $747,000 | -18.3% | 18,895 | -12.2% | 0.00% | 0.0% |
| Q2 2021 | $914,000 | -25.5% | 21,519 | +8.0% | 0.00% | -50.0% |
| Q1 2021 | $1,227,000 | -11.8% | 19,931 | +1.0% | 0.00% | 0.0% |
| Q4 2020 | $1,391,000 | +243.5% | 19,724 | +87.8% | 0.00% | +100.0% |
| Q3 2020 | $405,000 | +2.8% | 10,503 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $394,000 | – | 10,503 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
| CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
| VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
| Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
| Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
| RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
| Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
| Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
| Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
| Atom Investors LP | 49,981 | $3,526,000 | 0.36% |